SPRINGFIELD, Mass. (WWLP) – Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Officials investigate rare ...
Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...